NO964465L - Heparinbindende protein for behandling av sepsis, og fremgangsmåter for dets fremtilling - Google Patents

Heparinbindende protein for behandling av sepsis, og fremgangsmåter for dets fremtilling

Info

Publication number
NO964465L
NO964465L NO964465A NO964465A NO964465L NO 964465 L NO964465 L NO 964465L NO 964465 A NO964465 A NO 964465A NO 964465 A NO964465 A NO 964465A NO 964465 L NO964465 L NO 964465L
Authority
NO
Norway
Prior art keywords
heparin
binding protein
hbp
treatment
protein
Prior art date
Application number
NO964465A
Other languages
English (en)
Norwegian (no)
Other versions
NO964465D0 (no
Inventor
Hans Jakob Hem Flodgaard
Poul Baad Rasmussen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO964465D0 publication Critical patent/NO964465D0/no
Publication of NO964465L publication Critical patent/NO964465L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
NO964465A 1994-04-21 1996-10-21 Heparinbindende protein for behandling av sepsis, og fremgangsmåter for dets fremtilling NO964465L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK46494 1994-04-21
DK145294 1994-12-21
PCT/DK1995/000121 WO1995028949A1 (en) 1994-04-21 1995-03-17 Heparin-binding protein for the treatment of sepsis and processes for its preparation

Publications (2)

Publication Number Publication Date
NO964465D0 NO964465D0 (no) 1996-10-21
NO964465L true NO964465L (no) 1996-10-21

Family

ID=26064054

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964465A NO964465L (no) 1994-04-21 1996-10-21 Heparinbindende protein for behandling av sepsis, og fremgangsmåter for dets fremtilling

Country Status (15)

Country Link
EP (1) EP0762889B1 (cs)
JP (1) JPH09512168A (cs)
CN (1) CN1146724A (cs)
AT (1) ATE239494T1 (cs)
AU (1) AU703963B2 (cs)
CA (1) CA2188395A1 (cs)
CZ (1) CZ289439B6 (cs)
DE (1) DE69530689T2 (cs)
FI (1) FI964227A7 (cs)
HU (1) HU221638B1 (cs)
NO (1) NO964465L (cs)
NZ (2) NZ332683A (cs)
PL (1) PL316935A1 (cs)
RU (1) RU2200573C2 (cs)
WO (1) WO1995028949A1 (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607916A (en) * 1989-07-05 1997-03-04 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
WO1999000417A1 (en) * 1997-06-25 1999-01-07 Novo Nordisk A/S Production of heparin-binding protein in mammalian cells
WO1999000416A1 (en) * 1997-06-25 1999-01-07 Novo Nordisk A/S Use of heparin-binding protein for inhibiting entry of pathogens into mononuclear cells
IL146128A0 (en) * 1999-04-29 2002-07-25 Leukotech As Expression of heparin-binding protein in recombinant mammalian cells
RU2278675C1 (ru) * 2005-01-17 2006-06-27 Юрий Борисович Иванов Антимикробное средство и фармацевтическая композиция, содержащая эффективное количество антимикробного средства
GB0521276D0 (en) * 2005-10-19 2005-11-30 Lewitt Moira S Medical uses and therapies based upon the action of azurocidin on IGFBP-1
KR101067525B1 (ko) * 2005-12-22 2011-09-27 제넨테크, 인크. 헤파린 결합 단백질의 재조합 생산
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
GB201016161D0 (en) * 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
GB201102108D0 (en) * 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method
CN110903375A (zh) * 2019-10-12 2020-03-24 南京立顶生物科技有限公司 一种肝素结合蛋白生产提纯方法
CN110726846B (zh) * 2019-12-04 2022-08-26 南京市儿童医院 Hbp蛋白作为川崎病的诊断标志物的应用
CN113945718A (zh) * 2020-03-04 2022-01-18 上海奥普生物医药股份有限公司 一种肝素结合蛋白检测试剂盒、制备方法及用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219883B (hu) * 1988-03-17 2001-08-28 Novo-Nordisk A/S Heparinkötő proteinek, ezeket kódoló DNS és a proteineket tartalmazó gyógyszerkészítmények, valamint eljárás ezek előállítására
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
RU2008009C1 (ru) * 1989-06-19 1994-02-28 Кожемякин Александр Григорьевич Способ лечения септических заболеваний у новорожденных и детей грудного возраста
US5484885A (en) * 1989-07-05 1996-01-16 Emory University Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
GB9017008D0 (en) * 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
RU2012341C1 (ru) * 1991-07-15 1994-05-15 Ростовский научно-исследовательский институт акушерства и педиатрии Способ лечения сепсиса у новорожденных детей

Also Published As

Publication number Publication date
NO964465D0 (no) 1996-10-21
AU2303395A (en) 1995-11-16
FI964227A0 (fi) 1996-10-21
JPH09512168A (ja) 1997-12-09
FI964227L (fi) 1996-10-21
RU2200573C2 (ru) 2003-03-20
FI964227A7 (fi) 1996-10-21
HUT75557A (en) 1997-05-28
DE69530689T2 (de) 2004-03-25
CZ289439B6 (cs) 2002-01-16
HU221638B1 (hu) 2002-12-28
HU9602895D0 (en) 1996-12-30
EP0762889A1 (en) 1997-03-19
NZ332683A (en) 2001-06-29
CZ308296A3 (en) 1997-08-13
PL316935A1 (en) 1997-02-17
ATE239494T1 (de) 2003-05-15
CA2188395A1 (en) 1995-11-02
NZ284434A (en) 1998-12-23
CN1146724A (zh) 1997-04-02
AU703963B2 (en) 1999-04-01
DE69530689D1 (de) 2003-06-12
EP0762889B1 (en) 2003-05-07
WO1995028949A1 (en) 1995-11-02

Similar Documents

Publication Publication Date Title
NO964465L (no) Heparinbindende protein for behandling av sepsis, og fremgangsmåter for dets fremtilling
Habicht et al. Lyme disease spirochetes induce human and murine interleukin 1 production.
Liang et al. Binding of heparan sulfate to Staphylococcus aureus
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
EP1770164A3 (en) Streptococcus pneumoniae antigens and vaccines
NO981044D0 (no) Sirkulært DNA-molekyl med kondisjonell replikasjonsopprinnelse, dets fremstilling og anvendelse derav i genterapi
PT816380E (pt) Proteina ocif e metodos para a sua producao
EP1731166A3 (en) Streptococcus pneumoniae proteins and vaccines
ES2215324T3 (es) Mcp-2 amino-terminalmente truncadas como antagonistas de la quimioquina.
ATE246248T1 (de) Anti-hiv-proteine gap31, dap30 und dap32, die sie kodierende dna und ihre therapeutische nutzung
Van Damme et al. Characterization of granulocyte chemotactic activity from human cytokine-stimulated chondrocytes as interleukin 8
RU96122777A (ru) Связывающий гепарин белок для лечения сепсиса и способы его получения
MA22139A1 (fr) Procede co-hydrolytique pour la production de nouveaux extraits de proteines de la levure et de produits n'en contenant pas
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
MX9604953A (es) Proteina que une heparina, para el tratamiento de sepsis y procesos para su preparacion.
JP2969461B2 (ja) ヒトγ−インターフェロンとその製造方法並びに用途
DK610488D0 (da) Antikoagulatorisk protein pp4-x, dets fremstilling og anvendelse
Takeda et al. The production of a cytotoxic factor by mouse peritoneal macrophages and macrophage hybridomas treated with various stimulating agents
Yasuda et al. Partial purification and characterization of feline gamma-like interferon
WO2001079525A3 (en) Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
RU93054302A (ru) Рекомбинантный lgg-связывающий g белок стрептококка группы g
EP0603393A4 (en) INTERLEUKIN 6 HUMAN RECOMBINATION WITH HOMOGENEOUS N TERMINATION AND PRODUCTION OF THIS INTERLEUKIN.
TH17361A (th) โปรตีนจากรีคอมบิแนนท์ มิวแทนท์ ของpasteurella multocida กรรมวิธีสำหรับเตรียมลำดับดีเอนเอที่มีประมวลรหัสของโปรตีนเรพลิคอนที่มีลำดับดีเอนเอและเซลล์ที่ทรานสฟอร์มด้วยเรพลิคอนดังกล่าวชนิดเดียวกัน
WO1992006112A1 (en) Activated ctap and analogs thereof and their use
DE69126379D1 (de) Verfahren zur herstellung und reinigung des carboxyterminalen fragments der dna-polymerase i von streptococcus pneumoniae

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application